Tamarind Bio
+98%
est. 2Y upside i
AI Inference Platform for Drug Discovery
Rank
#655
Sector
Discovery Tools (Healthcare)
Est. Liquidity
~6Y
Data Quality
Data: LowTamarind Bio is one of the more compelling Series A equity opportunities in AI drug discovery infrastructure — 70% YoY growth, reported profitability at just 12 employees, and enterprise traction with Bayer, Boehringer Ingelheim, and Flagship Pioneering signal genuine product-market fit and pricing power.
Last updated: May 5, 2026
Tamarind Bio converts its marquee pilots with Bayer and Boehringer Ingelheim into large multi-year enterprise agreements, pushing ARR toward $8-10M and supporting a Series B at $180-220M valuation — roughly 3.5-4x the estimated ~$50M Series A post-money. Dimension Capital syndicates a $30-40M Series B at a premium multiple given the hot AI drug discovery infrastructure narrative.
The company grows ARR at 40-50% annually, adds 1-2 new pharma enterprise accounts, and raises a Series B at approximately $80-90M in late 2027 — roughly 1.6-1.8x the estimated ~$50M Series A post-money. Open-source model commoditization and in-house pharma IT competition limit pricing power and slow the land-and-expand motion.
AlphaFold 3, ESMFold, and RFdiffusion commoditize core structure prediction, pharma IT budgets tighten post-cycle, and the company struggles to scale beyond its 12-person founding team without a step-change in ARR. A flat or down round at $30-40M forces heavy dilution and options granted at the ~$50M entry are largely underwater.
Preference Stack Risk
highFunding Intensity
27%Total funding of $13.6M against an estimated ~$50M Series A post-money implies a ~27% preference stack ratio, meaning investors recoup $13.6M off the top before common shareholders see any proceeds in an acquisition below approximately $50M.
Dilution Risk
highAs a Series A company with likely 2-3 additional financing rounds before a liquidity event, employees should expect cumulative dilution of 40-60%+ relative to today's cap table position by the time of exit.
Secondary Liquidity
noneAt $13.6M in total funding and 12 employees, Tamarind Bio has no established secondary market; employees should treat equity as fully illiquid until an IPO or acquisition, most realistically 5-7 years out.
Engineering — 2 roles
- Infrastructure Engineer · San Francisco
- Software Engineer · San Francisco
Science — 1 role
- Computational Scientist · San Francisco
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Tamarind Bio's data — designed to show you've done your homework.
- 1
“Open-source tools like AlphaFold 3 and RFdiffusion are free and increasingly capable — what is the durable moat that prevents large pharma IT teams from stitching together open-source pipelines and replicating your platform's core functionality in-house?”
- 2
“What is the current ARR and net dollar retention rate from enterprise accounts, and how does subscription pricing scale with researcher seat count versus computational volume?”
- 3
“What is the post-money Series A valuation and the liquidation preference structure — participating or non-participating — and what is the current 409A fair market value used to price new option grants?”
Community
Valuation Sentiment
Our model estimates +98% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.